Oren G. Livnat is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the specialty pharmaceutical industry. Mr. Livnat conducted more than twelve years of research on both the sell-side and the buy-side. Prior to joining H.C. Wainwright, Mr. Livnat worked as a Senior Analyst covering specialty and generic pharma at Iguana Healthcare Partners, a dedicated healthcare long/short hedge fund. Mr. Livnat began his career as an Associate at Natixis Bleichroeder and successively worked as a Senior Analyst at JMP Securities covering both commercial and development-stage companies.
Analyst: Heiko Ihle
Analyst
Heiko Ihle is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on companies in the Metals and Mining industry. Prior to joining H.C. Wainwright, Mr. Ihle worked as a Senior Research Analyst at Euro Pacific Capital where his research was also focused on the Mining industry. Prior to that, Mr. Ihle worked at Gabelli & Company covering both the Industrials and E&C industries. Mr. Ihle also completed summer internships with Deutsche Bank on the foreign exchange trading desk and on fixed income sales, in New York and Germany, respectively.
Analyst: Andrew Fein
Analyst
Andrew Fein is a Managing Director of Equity Research at H.C. Wainwright. Mr. Fein conducted more than twelve years of biotechnology equity research. Prior to joining H.C. Wainwright, Mr. Fein worked as the Head of the Healthcare Research effort at Chardan Capital Markets. Mr. Fein began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. After that, Mr. Fein worked as a Managing Director/Senior Biotechnology Analyst at Jefferies, Piper Jaffray and Collins Stewart.
Analyst: Kevin Dede
Analyst
Kevin Dede is a Managing Director of Equity Research at H.C. Wainwright. Prior to joining H.C. Wainwright, Mr. Dede conducted over twenty years of institutional research covering different industries such as telecommunications food chain, heavy industry, retail, financial services, and almost all realms of technology. Mr. Dede began his career at Prudential Securities and successively worked for other sell-side investment banks such as Montgomery Securities, Merriman Curhan & Ford, and Auriga LLC.
Analyst: Amit Dayal
Analyst
Amit Dayal is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on small cap growth companies listed in the U.S. Prior to joining H.C. Wainwright, Mr. Dayal was both an advisor for and an investor in tech startups. Mr. Dayal was also a Senior Research Analyst at Rodman & Renshaw for seven years where his research focused on companies operating in emerging markets as well as small and mid-cap companies such as TMT (Technology Media Telecom), Clean Tech, Industrials and Consumer.
Analyst: Dr. Yi Chen, Ph.D.
AnalystDr. Yi Chen is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biotechnology and the pharmaceutical sectors. Dr. Chen’s research covers investment opportunities in the U.S. healthcare industry. Prior to joining H.C. Wainwright, Dr. Chen worked as an Associate Director of Equity Research at Aegis Capital Corp. and as a Research Associate at Morgan Joseph TriArtisan, LLC. Dr. Chen also worked as a Trading Associate at Zhang Capital Management, a New York-based buy-side fund. Prior to that, Dr. Chen was a Research Associate at the City University of New York where his research focused primarily on protein signaling domains utilizing an RNA interference approach.
Analyst: Dr. Debjit Chattopadhyay
Analyst
Dr. Debjit Chattopadhyay is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on biotechnology, specifically on gene therapy, immune-oncology, and rare diseases. Prior to joining H.C. Wainwright, Dr. Chattopadhyay has been a Wall Street Healthcare Analyst, on the sell-side, working for Janney Montgomery Scott, Roth Capital Partners, and Boenning & Scattergood. Most recently, Dr. Chattopadhyay worked as the Managing Director and the Head of Biotechnology at Janney Montgomery Scott.
Analyst: Vernon T. Bernardino
Analyst
Vernon T. Bernardino is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Specific therapeutic areas of interest include vascular diseases, gastrointestinal and autoimmune diseases, infectious diseases, metabolic and rare diseases. He possesses over 10 years of experience in the healthcare industry and over 12 years in sell-side and buy-side equity research. Prior to joining H.C. Wainwright, Mr. Bernardino was a healthcare equity research analyst at multiple Wall Street firms including Seaport Global Securities, B. Riley FBR, Rodman & Renshaw LLC, UBS Securities, and Nicholas Applegate Capital Management (now part of Allianz SE). For 2017, Mr. Bernardino was recognized by TipRanks as a Top 150 Wall Street analyst.
Analyst: Ed Arce
Analyst
Ed Arce is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biopharmaceutical and the specialty pharmaceutical sectors. In particular, Mr. Arce’s research covers investment opportunities among hepatology, renal, infectious disease, gastrointestinal, endocrine, metabolic and select rare disease companies Mr. Arce has been involved in institutionally-focused healthcare research since 2005. Prior to joining H.C. Wainwright, Mr. Arce was a Senior Research Analyst at ROTH Capital Partners. Mr. Arce’s previous sell-side experience includes working for MLV & Co, Wedbush Securities, UBS Securities and First Albany Capital.
H. C. Wainwright & Co.
Analyst
H.C. Wainwright & Co. is one of the country’s oldest financial institutions. H.C. Wainwright & Co. was founded in 1868 at the Union Bank Building in Boston, Massachusetts, located at the heart of the strongest financial center in post-Civil War America. H.C. Wainwright & Co., is a full-service investment bank dedicated to providing corporate fiance, strategic and licensing advisory, research, sales & trading, and related services to pubic and private companies. H.C. Wainwright & Co. has been the leader in the CMPU (confidentially marketed public offerings), RD (registered direct offering) and PIPE (private investment in public equity) transactions since 1998.
Victim: Greg Manning
Victim - Individual
Greg Manning owns one of the world’s most important auction houses for stamps, Greg Manning Auctions, Inc. (GMAI), is also a major auctioneer of coins, sports cards, movie posters, comic books, and other specialty collectibles. Greg Manning does business across the price spectrum but focuses on high-end specialty markets where its expertise and customer service can serve to differentiate the company from the competition. The company has a strong presence in Europe and Asia through joint ventures in Spain and China.
Media: Tim Connally
Media
Tim Connolly is the CEO of Corporate Strategies, LLC and thrives on solving difficult business problems others find impossible to fix. For over 30 years under his leadership, Corporate Strategies has created successful financial outcomes out of business crisis, litigation resolution and growth opportunities for a broad portfolio of businesses.
Victim: Elon Musk
Victim - Individual
Elon Reeve Musk is a South African-born American entrepreneur and businessman who founded X.com in 1999 (which later became PayPal), SpaceX in 2002 and Tesla Motors in 2003. Musk became a multimillionaire in his late 20s when he sold his start-up company, Zip2, to a division of Compaq Computers.
Investor: Warren Buffett
Investor
Warren Buffett is as the “Oracle of Omaha,” and he is one of the most successful investors of all time. Buffett runs Berkshire Hathaway, which owns more than 60 companies, including insurer Geico, battery maker Duracell and restaurant chain Dairy Queen. Mr. Buffett is the son of a U.S. congressman, he first bought stock at age 11 and first filed taxes at age 13. He pledges to give away most of his fortune. Last year (2019) he donated $3.6 billion, much of it to the foundation of friends Bill and Melinda Gates.
Media: C. Austin (Bud) Burrell
Media
C. Austin (Bud) Burrell is a corporate finance generalist with over 30 years of Wall Street and related experience. He was a senior derivatives specialist and development stage company investment banker for more than 35 years on Wall Street.He is a 1968 Graduate of the U.S. Military Academy and a graduate of the Army’s Finance Officer Advanced Course.
